2024, Number 8
<< Back Next >>
Med Int Mex 2024; 40 (8)
McArdle disease (type V glycogen storage disease)
Hernández LA, Zamora FPA, Guízar GLA
Language: Spanish
References: 12
Page: 542-546
PDF size: 187.70 Kb.
ABSTRACT
Background: McArdle disease, also known as type V glycogen storage disease, is
an autosomal recessive hereditary metabolic myopathy, in which there is minimal or
no production of the glycogen phosphorylase enzyme in muscle and is characterized
by exercise intolerance, in addition to elevated creatine kinase levels, which can lead
to rhabdomyolysis.
Clinical case: A 25-year-old male patient, cared at the Internal Medicine service for
myopathy and increased creatine kinase in whom the electromyography was normal
and the muscle biopsy did not provide specific data, but the diagnosis of McArdle
disease was concluded by genetic study.
Conclusions: In McArdle disease laboratory, electrodiagnostic, and imaging studies
may be normal and nonspecific. This disease should be suspected in young people
with intolerance to physical activity.
REFERENCES
Quinlivan R, Buckley J, James M, et al. McArdle’s disease:clinical review. J Neurol Neurosurg Psychiatry 2010; 81:1182-8. doi: 10.1136/jnnp.2009.195040
Tarnopolsky MA. Metabolic myopathies. Muscle NeuromuscularJunction Disorders 2022; 28 (6): 1752-1777. doi:10.1212/CON.0000000000001182
Diez Morrondo C, Pantoja Zarza L, San Millán Tejado B.Enfermedad de McArdle: presentación de 2 casos clínicos.Reumatol Clin 2016; 12 (3): 161-163. DOI: 10.1016/j.reuma.2015.06.003
Llavero F, Arrazola A, Luque M, Gálvez P, et al. McArdledisease: new insights into its underlying molecularmechanisms. Int J Mol Sci 2019; 20: 5919. doi: 10.3390/ijms20235919
Leite A, Oliveira N, Rocha M. McArdle disease: a case reportand review. Int Med Case Rep J 2012; 1-4. doi: 10.2147/IMCRJ.S28664
Martín MA, Lucia A, Arenas J, et al. Glycogen storage diseasetype V. 2006. In: Adam MP, Everman DB, Mirzaa GM,et al., editors. GeneReviews® Seattle (WA): University ofWashington, Seattle; 1993-2022.
Calheiros-Cruz T, Caamaño-Vara MP, Villar-Fernández B,et al. McArdle’s disease (glycogen storage disease typeV): A clinical case. Arch Case Rep 2018; 2: 019-023. DOI:10.29328/journal.acr.1001010
Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypicfeatures of McArdle disease: insights from the Spanishnational registry. J Neurol Neurosurg Psychiatry 2012; 83(3): 322-8. doi: 10.1136/jnnp-2011-301593
Liu JJ, Jones JS, Rao PK. Urinalysis in the evaluation ofhematuria. JAMA 2016; 315 (24): 2726-7. doi:10.1001/jama.2016.5050
Lucia A, Nogales-Gadea G, Pérez M, et al. McArdle disease:what do neurologists need to know? Nat Clin Pract Neurol2008; 4 (10): 568-577. doi: 10.1038/ncpneuro0913
Quinlivan R, Martinuzzi A, Schoser B. Pharmacological andnutritional treatment for McArdle disease (glycogen storagedisease type V). Cochrane Database of Syst Rev 2014.doi: 10.1002/14651858.CD003458.pub5
Martinuzzi A, Liava A, Trevisi E, et al. Randomized, placebocontrolled,double-blind pilot trial of ramipril in McArdle’sdisease. Muscle Nerve 2008; 37 (3): 350-357. doi: 10.1002/mus.20937
Full text